Mesoporous silica/organosilica nanoparticles for cancer immunotherapy
Exploration · 2023-06 · 3 (3)
DOI: 10.1002/exp.20220086 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Exploration, online erschienen am 09.05.2023. Verfasst von Shevanuja Theivendran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Brisbane St Lucia Australia. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, Queensland Government.
Abstract (Originalsprache)
Cancer is one of the fatal diseases in the history of humankind. In this regard, cancer immunotherapeutic strategies have revolutionized the traditional mode of cancer treatment. Silica based nano‐platforms have been extensively applied in nanomedicine including cancer immunotherapy. Mesoporous silica nanoparticles (MSN) and mesoporous organosilica nanoparticles (MON) are attractive candidates due to the ease in controlling the structural parameters as needed for the targeted immunotherapeutic applications. Especially, the MON provide an additional advantage of controlling the composition and modulating the biological functions to actively synergize with other immunotherapeutic strategies. In this review, the applications of MSN, MON, and metal‐doped MSN/MON in the field of cancer immunotherapy and tumor microenvironment regulation are comprehensively summarized by highlighting the structural and compositional attributes of the silica‐based nanoplatforms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Brisbane St Lucia Australia.
ORCID-Profile: Chengzhong Yu
Förderung
- Australian Research Council
- Queensland Government
Zitieren
APA
Theivendran, S., Lazarev, S., & Yu, C. (2023). Mesoporous silica/organosilica nanoparticles for cancer immunotherapy. Exploration, 3(3). https://doi.org/10.1002/exp.20220086
Vancouver
Theivendran S, Lazarev S, Yu C. Mesoporous silica/organosilica nanoparticles for cancer immunotherapy. Exploration. 2023;3(3). doi:10.1002/exp.20220086
BibTeX
@article{Theivendran2023,
author = {Theivendran, Shevanuja and Lazarev, Sergei and Yu, Chengzhong},
title = {Mesoporous silica/organosilica nanoparticles for cancer immunotherapy},
journal = {Exploration},
year = {2023},
volume = {3},
number = {3},
doi = {10.1002/exp.20220086}
}
EUVIMED